ArticleJournal of hepatocellular carcinoma2026
Trans-Arterial Chemoembolization Combined with Microwave Ablation versus Microwave Ablation Alone for 3-5 cm Hepatocellular Carcinoma: A Multicenter Retrospective Study.
Article in Journal of hepatocellular carcinoma, 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
0 citing papers in PubMed.
No citing paper in PubMed yet.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
13 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
Objective: To compare safety and efficacy of transarterial chemoembolization (TACE) combined with microwave ablation (MWA) (TACE+MWA) versus only MWA treating hepatocellular carcinoma (HCC) 3-5 cm. Methods: A retrospective analysis was conducted on data collected from 202 HCC patients who attended four hospitals between January 2014 and December 2017. Diagnosis of all lesions was based on histopathology and radiology. In total, 202 patients with HCC 3-5 cm were included in this retrospective cohort study. These patients were classified into TACE+MWA and MWA groups based on the treatment. Patients were followed up with contrast enhanced CT or MRI. Images were evaluated and compared for treatment response and Adverse Events (AEs). Observe the occurrence of overall survival (OS), progression free survival (PFS) and AEs after the patient's treatment. Survival analysis was performed using Kaplan-Meier method. Multivariate Cox proportional hazards regression analysis was performed to explore the relevant factors influencing the prognosis of patients. Results: A total of 202 patients (median age, 58 years; 178 male) were included, with 102 in the TACE+MWA group and 100 in the MWA group. Baseline characteristics were well balanced between the two groups. Complete response (CR) was achieved by 78.4% of patients who received combined therapy compared with 76% with only MWA. The median PFS was 49.2 months (95% CI: 45.4-53.0) in the TACE+MWA group and 46.3 months (95% CI: 42.1-50.5) in the MWA group, with no significant difference ( Conclusion: TACE combined with MWA was associated with improved OS compared with MWA alone in patients with 3-5 cm HCC, while maintaining a comparable safety profile. These findings suggest that combination therapy may be a promising treatment strategy, although further prospective studies are needed to confirm these results.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.